GBGeorge Blackledge

George Blackledge

*This is an algorithmically generated author record based on publicly available information.

George Blackledge has a total of 3 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Developing an Oncology Portfolio of Anticancer Drugs: The Experience of one Pharmaceutical Company

    by G. R. P. Blackledge

    For a company or institute that wishes to develop new anti-cancer agents, it is necessary to establish a portfolio of agents to reduce the risk of failure. Success rates for developing new agents are low and therefore different biological effect areas should be explored to ensure that at least one agent targeting cancer or a specific histological sub-type of cancer is effectively developed. This paper describes how one pharmaceutical company has developed a range of different agents with the ultimate aim of developing as many of these as is technically feasible into useful new medicines for the treatment of cancer. Für ein Unternehmen oder Institut, welches Anti-Tumor-Therapien entwickeln möchte, ist es nötig ein Portfolio der Therapien zu erstellen, um das Risiko des Misserfolges zu minimieren. Die Erfolgsraten für Entwicklungen neuer Therapien sind niedrig; deshalb müssen verschiedene physiologische Wege und Wirkmechanismen erforscht werden um sicherzustellen, dass wenigstens eine Tumortherapie oder ein spezieller Tumoruntertyp effektvoll entwickelt werden kann. Diese Arbeit beschreibt die Entwicklung verschiedener Tumortherapien durch eine pharmazeutische Firma. Das ultimative Ziel hierbei war, so viele Therapien wie möglich zu entwickeln und diese auch als neue, nützliche Medizin für die Behandlung von Brustkrebs einzusetzen.

  • Open Access

    The difficulties industry is facing with investigators

    by George R.P. Blackledge


  • Open Access

    Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors

    by G Blackledge, S Averbuch

    The epidermal growth factor receptor (EGFR) is a promising target for cancer therapy and a number of EGFR-targeted agents have been developed. Those most advanced in development are the EGFR tyrosine kinase inhibitors gefitinib (‘Iressa’, ZD1839) and erlotinib (‘Tarceva’, OSI-774), and the monoclonal antibody cetuximab (‘Erbitux’, IMC-C225). This review provides a clinical overview of these agents, highlighting their antitumour activities in different tumour types. Epidermal growth factor receptor–targeted agents are generally well tolerated and are not typically associated with the severe adverse events often seen with cytotoxic chemotherapy. Gefitinib is the agent with the most extensive clinical experience, particularly in non-small-cell lung cancer (NSCLC). Recently, gefitinib became the first-approved EGFR-targeted agent, for use in patients with previously treated advanced NSCLC in Japan, the USA and other countries. Further studies are required to explore the full potential of these novel agents either as monotherapy or combination therapy.


  • Growth Factor Receptor Tyrosine Kinase Inhibitors; Clinical Development and Potential for Prostate Cancer Therapy

    by George Blackledge

    The development of effective, novel, targeted cancer therapies with minimal side effects has long been a goal in cancer research. A key group of targets identified for drug development consists of the receptor tyrosine kinases, which have pivotal roles in the growth factor signaling that is subverted in carcinogenesis and in the host processes, such as angiogenesis, involved in tumor progression. A literature review of the role of receptor tyrosine kinases in human malignancies is followed by a discussion of the potential use of inhibitors of receptor tyrosine kinases as anticancer therapy, focusing on the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839, AstraZeneca, Macclesfield, United Kingdom). Several small molecule inhibitors that are specific to individual receptor tyrosine kinases have been developed and a number of these potential anticancer agents are progressing through clinical trials. Various surrogate end points are being assessed to demonstrate the activity of these inhibitors against their targets. Results from studies of gefitinib alone and with the antiandrogen bicalutamide in both hormone dependent and independent prostate tumor xenografts suggested that gefitinib may have potential as monotherapy and combination therapy in the treatment of both forms of the disease. Gefitinib is currently undergoing further preclinical and clinical evaluation for the treatment of prostate cancer. A number of tyrosine kinase inhibitors, including gefitinib, are progressing through clinical development and are beginning to provide new treatment options for a range of malignancies.


  • Anti-EGF receptor therapy

    by G Blackledge, S Averbuch, A Kay, J Barton

    Prostate Cancer and Prostatic Diseases, covering all aspects of prostatic diseases, in particular prostate cancer. The journal is of interest to surgeons, oncologists, clinicians, and researchers involved in disease of the prostate.